

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/003,810 01/07/98 RAMAKRISHNAN V 44481-5017-0

009629 HM12/0817  
MORGAN, LEWIS & BOCKIUS  
1800 M STREET NW  
WASHINGTON DC 20036-5869

EXAMINER	
GAMBEL, P	
ART UNIT	PAPER NUMBER

1644  
**DATE MAILED:** 08/17/00  
21

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner of Patents and Trademarks**



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

09/00 3800

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER
1644	20

DATE MAILED:

**Please find below a communication from the EXAMINER in charge of this application**

Commissioner of Patents

In re Application of  
RAMAKRISHNAN ET AL.  
Serial No. 09/003,810  
Filed: January 7, 1998  
For: METHODS OF TREATING PDGF-MEDIATED DISEASES WITH BETA-PDGF RECEPTOR IMMUNOGLOBULIN POLYPEPTIDES

**SUSPENSION OF PROSECUTION**

All claims are allowable. However due to a potential interference, ex parte prosecution is SUSPENDED pending a determination as to whether an interference proceeding is appropriate.

In view of applicant's Petition to Correct Inventorship Under 37 CAR 1.48(b), filed 6/2/98; the inventorship in this nonprovisional application has been changed by the deletion of Lokker.

The inventors of the claimed invention are Ramakrishnan, Escobedo and Fretto.

Applicant's submission, filed 9/27/99 (Paper No. 7), has placed the instant application in compliance with the Sequence Rules.

It is apparent that the 2A1E2 antibody is required to practice the claimed invention (claim 38). As a required element, it must be known and readily available to the public or obtainable by a repeatable method set forth in the specification. If it is not so obtainable or available, the enablement requirements of 35 USC 112, first paragraph, may be satisfied by a deposit of the appropriate cell line / hybridoma which produces this antibody. See 37 CAR 1.801-1.809.

Given the patented claims set forth in U.S. Patent 5,817,310, the deposit requirements for the 2A1E2 antibody produced by the hybridoma ATCC NO. 10938 have been satisfied.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gabel whose telephone number is (703) 308-3997. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Phillip Gabel, PhD.  
Primary Examiner  
Technology Center 1600  
August 14, 2000

*Phillip Gabel*